Laura MuÃ±oz-Delgado

List of Publications by Year
in descending order

81 papers	2,929 citations	304743 22 h-index	197818 49 g-index
82 all docs	82 docs citations	82 times ranked	7187 citing authors

#	Article	IF	Citations
1	Analysis of shared heritability in common disorders of the brain. Science, 2018, 360, .	12.6	1,085
2	In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinsonâ€™s disease. Brain, 2018, 141, 165-176.	7.6	135
3	Effects of Two Weeks of Cerebellar Theta Burst Stimulation in Cervical Dystonia Patients. Brain Stimulation, 2014, 7, 564-572.	1.6	124
4	Genomeâ€wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project. Alzheimer's and Dementia, 2019, 15, 1333-1347.	0.8	111
5	Tremor stability index: a new tool for differential diagnosis in tremor syndromes. Brain, 2017, 140, 1977-1986.	7.6	103
6	The long-term outcome of orthostatic tremor. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-309942.	1.9	100
7	GBA Variants Influence Motor and Non-Motor Features of Parkinsonâ€™s Disease. PLoS ONE, 2016, 11, e0167749.	2.5	91
8	N370Sâ€GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease. Movement Disorders, 2017, 32, 1409-1422.	3.9	86
9	COPPADIS-2015 (COhort of Patients with PArkinsonâ€™s DIsease in Spain, 2015), a global â€“clinical evaluations, serum biomarkers, genetic studies and neuroimagingâ€“ prospective, multicenter, non-interventional, long-term study on Parkinsonâ€™s disease progression. BMC Neurology, 2016, 16, 26.	1.8	66
10	Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. Journal of Neurology, 2015, 262, 2201-2213.	3.6	59
11	Consensus on the Definition of Advanced Parkinsonâ€™s Disease: A Neurologists-Based Delphi Study (CEPA Study). Parkinson's Disease, 2017, 2017, 1-8.	1.1	53
12	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Populationâ€Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. Movement Disorders, 2019, 34, 1851-1863.	3.9	47
13	Clinical, genetic and neuropathological characterization of spinocerebellar ataxia type 37. Brain, 2018, 141, 1981-1997.	7.6	40
14	Pre- and perinatal complications in relation to Tourette syndrome and co-occurring obsessive-compulsive disorder and attention-deficit/hyperactivity disorder. Journal of Psychiatric Research, 2016, 82, 126-135.	3.1	36
15	European Multicentre Tics in Children Studies (EMTICS): protocol for two cohort studies to assess risk factors for tic onset and exacerbation in children and adolescents. European Child and Adolescent Psychiatry, 2019, 28, 91-109.	4.7	36
16	Peripheral Immune Profile and Neutrophilâ€toâ€Lymphocyte Ratio in Parkinson's Disease. Movement Disorders, 2021, 36, 2426-2430.	3.9	36
17	Directional Deep Brain Stimulation for Parkinson's Disease: Results of an InternationalÂCrossover Study With Randomized, Double-Blind Primary Endpoint. Neuromodulation, 2022, 25, 817-828.	0.8	34
18	Synaptic processes and immune-related pathways implicated in Tourette syndrome. Translational Psychiatry, 2021, 11, 56.	4.8	31

#	Article	IF	Citations
19	Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. JAMA Neurology, 2022, 79, 652.	9.0	31
20	Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	30
21	Long-term effectiveness of levodopaâ€“carbidopa intestinal gel in 177 Spanish patients with advanced Parkinson's disease. Neurodegenerative Disease Management, 2016, 6, 289-298.	2.2	25
22	Abnormal cerebellar connectivity and plasticity in isolated cervical dystonia. PLoS ONE, 2019, 14, e0211367.	2.5	25
23	Role of ANO3 mutations in dystonia: A large-scale mutational screening study. Parkinsonism and Related Disorders, 2019, 62, 196-200.	2.2	25
24	Genetic factors influencing frontostriatal dysfunction and the development of dementia in Parkinson's disease. PLoS ONE, 2017, 12, e0175560.	2.5	24
25	Investigation of previously implicated genetic variants in chronic tic disorders: a transmission disequilibrium test approach. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 301-316.	3.2	23
26	Lower levels of uric acid and striatal dopamine in non-tremor dominant Parkinson's disease subtype. PLoS ONE, 2017, 12, e0174644.	2.5	22
27	Improvement of impulse control disorders associated with levodopaâ€“carbidopa intestinal gel treatment in advanced Parkinsonâ€™s disease. Journal of Neurology, 2018, 265, 1279-1287.	3.6	19
28	A Bayesian spatial model for neuroimaging data based on biologically informed basis functions. NeuroImage, 2017, 161, 134-148.	4.2	18
29	Increased bilirubin levels in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 63, 213-216.	2.2	18
30	Predictors of clinically significant quality of life impairment in Parkinsonâ€™s disease. Npj Parkinson's Disease, 2021, 7, 118.	5.3	17
31	InÂvivo cholinergic basal forebrain degeneration and cognition in Parkinson's disease: Imaging results from the COPPADIS study. Parkinsonism and Related Disorders, 2021, 88, 68-75.	2.2	16
32	Lack of Association of Group A Streptococcal Infections and Onset of Tics. Neurology, 2022, 98, .	1.1	16
33	Clinical features and neuropsychological profile in vascular parkinsonism. Journal of the Neurological Sciences, 2014, 345, 193-197.	0.6	15
34	The role of mutations in COL6A3 in isolated dystonia. Journal of Neurology, 2016, 263, 730-734.	3.6	15
35	Serum lipid profile among sporadic and familial forms of Parkinsonâ€™s disease. Npj Parkinson's Disease, 2021, 7, 59.	5.3	15
36	Parieto-motor Cortical Dysfunction in Primary Cervical Dystonia. Brain Stimulation, 2014, 7, 650-657.	1.6	14

#	Article	IF	Citations
37	A geroscience approach for Parkinsonâ€™s disease: Conceptual framework and design of PROPAG-AGEING project. Mechanisms of Ageing and Development, 2021, 194, 111426.	4.6	14
38	Early downregulation of hsa-miR-144-3p in serum from drug-naÃ¯ve Parkinsonâ€™s disease patients. Scientific Reports, 2022, 12, 1330.	3.3	14
39	The impact of freezing of gait on functional dependency in Parkinsonâ€™s disease with regard to motor phenotype. Neurological Sciences, 2020, 41, 2883-2892.	1.9	13
40	Impaired motor cortical plasticity associated with cannabis use disorder in young adults. Addiction Biology, 2021, 26, e12912.	2.6	13
41	A Modified Progressive Supranuclear Palsy Rating Scale. Movement Disorders, 2021, 36, 1203-1215.	3.9	13
42	Increased homocysteine levels correlate with cortical structural damage in Parkinson's disease. Journal of the Neurological Sciences, 2022, 434, 120148.	0.6	13
43	GDNF gene is associated with tourette syndrome in a family study. Movement Disorders, 2015, 30, 1115-1120.	3.9	11
44	Short-afferent inhibition and cognitive impairment in Parkinson's disease: A quantitative review and challenges. Neuroscience Letters, 2020, 719, 133679.	2.1	11
45	3D Printing of Diffuse Low-Grade Gliomas Involving Eloquent Cortical Areas and Subcortical Functional Pathways: Technical Note. World Neurosurgery, 2021, 147, 164-171.e4.	1.3	11
46	Low serum uric acid levels in progressive supranuclear palsy. Movement Disorders, 2016, 31, 402-405.	3.9	10
47	Impact of Disease Duration in Effectiveness of Treatment with Levodopa-Carbidopa Intestinal Gel and Factors Leading to Discontinuation. Journal of Parkinson's Disease, 2019, 9, 173-182.	2.8	10
48	Predictors of Global Non-Motor Symptoms Burden Progression in Parkinsonâ€™s Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up. Journal of Personalized Medicine, 2021, 11, 626.	2.5	10
49	Traitâ€•and stateâ€•dependent cortical inhibitory deficits in bipolar disorder. Bipolar Disorders, 2016, 18, 261-271.	1.9	9
50	Predictors of Loss of Functional Independence in Parkinsonâ€™s Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up and Comparison with a Control Group. Diagnostics, 2021, 11, 1801.	2.6	9
51	Increased Stroke Risk in Patients with Parkinson's Disease with <scp>LRRK2</scp> Mutations. Movement Disorders, 2022, 37, 225-227.	3.9	9
52	Clinical Practice Patterns in Tic Disorders Among Movement Disorder Society Members. Tremor and Other Hyperkinetic Movements, 2021, 11, 43.	2.0	8
53	TMEM230 in Parkinsonâ€™s disease in a southern Spanish population. PLoS ONE, 2018, 13, e0197271.	2.5	7
54	Mood in Parkinson's disease: From earlyâ€•to lateâ€•stage disease. International Journal of Geriatric Psychiatry, 2021, 36, 627-646.	2.7	7

#	Article	IF	Citations
55	Association of <scp>PICALM</scp> with Cognitive Impairment in Parkinson's Disease. Movement Disorders, 2021, 36, 118-123.	3.9	7
56	NR4A2 Mutations Can Cause Intellectual Disability and Language Impairment With Persistent Dystonia-Parkinsonism. Neurology: Genetics, 2021, 7, e543.	1.9	7
57	Assessment of intellectual impairment, healthâ€related quality of life, and behavioral phenotype in patients with neurotransmitter related disorders: Data from the <scp>iNTD</scp> registry. Journal of Inherited Metabolic Disease, 2021, 44, 1489-1502.	3.6	7
58	Predictors of the change in burden, strain, mood, and quality of life among caregivers of Parkinson's disease patients. International Journal of Geriatric Psychiatry, 2022, 37, .	2.7	7
59	Analysis of c.801-2A>G mutation in the DNAJC6 gene in Parkinson's disease in southern Spain. Parkinsonism and Related Disorders, 2014, 20, 248-249.	2.2	6
60	Genetic analysis of CHCHD2 in a southern Spanish population. Neurobiology of Aging, 2017, 50, 169.e1-169.e2.	3.1	6
61	Present and Future of Parkinsonâ€™s Disease in Spain: PARKINSON-2030 Delphi Project. Brain Sciences, 2021, 11, 1027.	2.3	6
62	Screening study of TUBB4A in isolated dystonia. Parkinsonism and Related Disorders, 2017, 41, 118-120.	2.2	5
63	Quantitative Intensity Harmonization of Dopamine Transporter SPECT Images Using Gamma Mixture Models. Molecular Imaging and Biology, 2019, 21, 339-347.	2.6	5
64	Falls Predict Acute Hospitalization in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2021, , 1-20.	2.8	5
65	Abnormal sensorimotor integration correlates with cognitive profile in vascular parkinsonism. Journal of the Neurological Sciences, 2017, 377, 161-166.	0.6	3
66	A replication study of GWAS-genetic risk variants associated with Parkinsonâ€™s disease in a Spanish population. Neuroscience Letters, 2019, 712, 134425.	2.1	3
67	Analysis of p.Tyr307Asn variant in the LRP10 gene in Parkinsonâ€™s disease in southern Spain. Neurobiology of Aging, 2020, 93, 142.e1-142.e3.	3.1	3
68	The role of RHOT1 and RHOT2 genetic variation on Parkinson disease risk and onset. Neurobiology of Aging, 2021, 97, 144.e1-144.e3.	3.1	3
69	Parkinsonâ€™s Disease Motor Subtypes Change with the Progression of the Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up. Journal of Parkinson's Disease, 2022, 12, 935-955.	2.8	3
70	MNCD: A New Tool for Classifying Parkinsonâ€™s Disease in Daily Clinical Practice. Diagnostics, 2022, 12, 55.	2.6	3
71	On the long-term outcome of orthostatic tremor. Parkinsonism and Related Disorders, 2015, 21, 1290-1291.	2.2	2
72	Mutational spectrum of GNAL , THAP1 and TOR1A genes in isolated dystonia: study in a population from Spain and systematic literature review. European Journal of Neurology, 2021, 28, 1188-1197.	3.3	2

#	Article	IF	Citations
73	Levodopa-Induced Dyskinesia in Parkinson Disease Specifically Associates With Dopaminergic Depletion in Sensorimotor-Related Functional Subregions of the Striatum. Clinical Nuclear Medicine, 2021, 46, e296-e306.	1.3	2
74	Investigation of geneâ€“environment interactions in relation to tic severity. Journal of Neural Transmission, 2021, 128, 1757-1765.	2.8	2
75	Heterogeneity of prodromal Parkinson symptoms in siblings of Parkinson disease patients. Npj Parkinson's Disease, 2021, 7, 78.	5.3	2
76	Diplopia Is Frequent and Associated with Motor and Non-Motor Severity in Parkinsonâ€™s Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up. Diagnostics, 2021, 11, 2380.	2.6	2
77	Automatic and voluntary motor inhibition: Intact processes for tic suppression?. Movement Disorders, 2018, 33, 1667-1669.	3.9	1
78	Raising serum urate levels in Parkinson disease. Neurology, 2019, 93, 611-612.	1.1	1
79	Orthostatic Myoclonus Secondary to Central Pontine Myelinolysis. Movement Disorders Clinical Practice, 2020, 7, 335-337.	1.5	1
80	Teaching Video NeuroImages: Clues in Myoclonus Evaluation: When to Consider Sialidosis. Neurology, 2021, 97, 10.1212/WNL.0000000000012464.	1.1	0
81	Reply to: â€œIncreased Stroke Risk in Patients with Parkinson's Disease with LRRK2 Mutationsâ€. Movement Disorders, 2022, 37, 1119-1120.	3.9	0